Ocumension Therapeutics (HKG:1477) said Friday that the Chinese healthcare regulator approved its new drug application for OT-301, its proposed treatment for glaucoma or ocular hypertension-related complications, according to a same-day bourse filing.
The pharmaceutical company said the approval follows the completion of the Mont Blanc and Denali trials of OT-301, in which the treatment achieved key study goals.
The company's shares are down 2.8% in afternoon trading on the HKEX.